Cure SMA is thrilled to welcome Biogen back as a National Premier Partner for 2018.
As a part of their partnership, Biogen will be sponsoring all walk-n-rolls and galas across the US for the entirety of 2018, as well as the Hope on the Hill Congressional Dinner. Biogen is also a key participant in many of Cure SMA’s ongoing programs, including the SMA Industry Collaboration, the SMA Newborn Screening Coalition, and our bi-annual family newsletter, Directions. Finally, Biogen will once again be part of the Annual SMA Conference as the 2018 Presenting Sponsor.
“For many years now, Biogen has provided vital support for the research, programs, and advocacy that are critical to our community’s goals,” said Kenneth Hobby, president of Cure SMA. “We’re excited they’ve chosen to continue their partnership with us into 2018. Biogen’s work led to the milestone approval of Spinraza, and with their support of both new and longstanding programs, we look forward to many more milestones together.”
In December 2016, the FDA announced that it had approved Spinraza, the first-ever approved therapy to treat SMA. To learn more about the approval of Spinraza, visit www.Spinraza.com or www.cureSMA.org/spinraza.
Through collaboration with our partners, like Biogen, Cure SMA is working toward a world without SMA. On behalf of the entire community, we thank Biogen for their ongoing partnership.